Alwan Therapeutics is developing a phase-specific migraine formula designed to support patients across interictal and attack phases. Join our waiting list, share your history, and be among the first to learn about our upcoming clinical trial.
We are advancing a thoughtfully designed formula intended to address the oscillating nature of migraine across its different phases.
Formulated with the interictal period and attack phases (premonitory, headache, postdrome) in mind.
Built on ingredients and approaches studied in migraine literature, with a focus on bioavailability and tolerability.
We listen to real treatment histories and symptom patterns to guide development and trial design.
We are exploring AI-supported clinical trial methods to help plan and interpret a future human study. Modeled results are not a substitute for that study.
Read personal accounts people have chosen to share, or add your own. These are individual stories, not clinical trial results, and they do not establish safety or effectiveness.
No public testimonials yet. Stories you approve will appear here.
Submit a short account below.
We are preparing a human clinical study to evaluate safety, tolerability, and other measured outcomes of our investigational migraine formula. We are also exploring how AI can support the design and analysis of that study.
Eligible participants who join the waiting list may be contacted when enrollment opens. The study design, inclusion criteria, and locations will be shared with qualified individuals. Participation is voluntary and subject to screening and informed consent.
Clinical trials are carefully regulated. Full details, risks, and benefits will be provided in official study materials and the informed consent form.
Express Interest via WaitlistAlwan is exploring AI-supported clinical trial methods to help plan, design, and interpret a future ethics-reviewed human study. Used carefully, these tools can make a trial more efficient and help us ask better questions. They do not replace human participants, ethics review, or regulatory review.
AI can help review published migraine research and pattern data so we can refine study questions, endpoints, and eligibility criteria before anyone enrolls.
Methods such as digital twins or synthetic comparison groups are being studied as a possible way to reduce how many people need to receive placebo and to make better use of a smaller human cohort. Any such approach would still require a real human study and review by ethics committees and regulators.
Modeled data can be compared with what is seen in a human cohort to help flag questions about side-effect patterns across a wider range of simulated people, without exposing additional participants. That work can generate questions for the study team. It does not establish a safety profile.
Models can explore how symptoms cluster, such as differences in associated symptoms, which may help us study subgroups more thoughtfully. Those explorations are hypotheses. They do not show who would benefit.
If a human study later produces laboratory or other measured data, those findings can be fed back into models to explore possible dose or formulation questions for later, separately reviewed studies.
Running design scenarios on a computer lets us iterate on the protocol before exposing people to an investigational product, which may save time and planning cost.
The planned path has three steps: first, AI-informed planning and simulated study scenarios; second, a human validation study under applicable ethics and regulatory review, including possible sites in Australia; and third, comparing the human results with the models so later study questions can be refined. Human results would be what anchors any model. AI-generated or simulated data alone is not clinical evidence, and it is not a substitute for review by bodies such as the FDA or Australia’s TGA.
Support the development of better options for people living with migraine.
We are exploring strategic partnerships and investment opportunities to advance our migraine formula through clinical development and potential commercialization. That work includes a planned human clinical study, supported where appropriate by AI-supported clinical trial methods that may improve study design, planning efficiency, and how we interpret results. If you are an accredited investor, family office, or strategic partner interested in learning more, please indicate your interest on the waitlist form or contact us directly.
This is not an offer to sell securities. Any offering will be made only pursuant to applicable securities laws and offering documents.
Indicate Investment InterestComplete the questionnaire below. Your responses help us understand real-world needs and may inform trial eligibility outreach.